AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25733676
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as an add-on treatment to a selective serotonin reuptake inhibitor
Trial: 22897785
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with cow's milk protein increased from 0.06 mg to a maximum of 6400 mg over 23 weeks.
Trial: 22897785
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (control) receiving no active treatment.
Trial: 21898715
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interpersonal psychotherapy and SSRI
Trial: 10889153
Drug: r-metHuBDNF (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHuBDNF (100 microg/kg SC daily for 2 weeks)
Trial: 10889153
Drug: r-metHuNT-3 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHuNT-3 (300 microg/kg SC thrice weekly for 2 weeks)
Trial: 30118582
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (1 g) + IV hydromorphone (0.5 mg)
Trial: 30118582
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL normal saline) + IV hydromorphone (0.5 mg)
Trial: 29152847
Drug: brexpiprazole +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole + antidepressant therapy
Trial: 29152847
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + antidepressant therapy
Trial: 16103770
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitor regimens (lopinavir, indinavir, saquinavir, amprenavir at 50%, 32%, 11%, and 6% respectively)
Trial: 16103770
Drug: Fold change
RxNorm normalized name: Folditam
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fold change (FC) and trough drug concentration (Cmin)
Trial: 11855668
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg/day, p.o.) for 3 months
Trial: 8606538
Drug: Diltiazem 300
RxNorm normalized name: diltiazem 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 300 mg once daily (n = 16)
Trial: 8606538
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg once daily (n = 20)
Trial: 268331
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral hygiene and no chewing (control)
Trial: 8290186
Drug: 20-minute regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute regimen for labor augmentation
Trial: 8290186
Drug: 40-minute regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-minute regimen for labor augmentation
Trial: 1494489
Drug: Oxytocin (3-fold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (3-fold higher dosage)
Trial: 152602
Drug: Muscimol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscimol treatment
Trial: 30616657
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of ferric carboxymaltose (single dose)
Trial: 30616657
Drug: 200 g/48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g/48 h of iron sucrose (fractionated doses)
Trial: 28239907
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 1200 mg/day
Trial: 19485842
Drug: Biomarker-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker-guided treatment strategies
Trial: 19485842
Drug: Conventional test-guided
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional test-guided treatment strategies
Trial: 17691581
Drug: Hydroxyl-chloroquine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyl-chloroquine (6 mg/kg per day), oral transfer agent liquid, Vit B1, Vit B2, Vit C, fish-liver oil, and pilocarpine (20 mg/d) for 2 months
Trial: 15381891
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual without distraction
Trial: 11433050
Drug: Sn-mesoporphyrin (SnMP)
RxNorm normalized name: Sn Mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sn-mesoporphyrin (SnMP) administered as a single intramuscular dose of 6 micromol/kg birth weight within 24 +/- 12 hours of age
Trial: 11433050
Drug: G‐6‐PD‐normal newborns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐6‐PD‐normal newborns (control group)
Trial: 11433050
Drug: G‐6‐PD‐deficient newborns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐6‐PD‐deficient newborns (comparison group)
Trial: 5297557
Drug: Danish BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danish BCG vaccine
Trial: 5297557
Drug: Swedish BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish BCG vaccine
Trial: 5297557
Drug: Czechoslovak BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Czechoslovak BCG vaccine
Trial: 31655974
Drug: Ixekizumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (80 mg every 4 weeks or 12 weeks)
Trial: 22334228
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and Metformin 1000 mg/day (D+M)
Trial: 22334228
Drug: Diet, Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet, Metformin 500 mg/day and MYO 4 g/day plus 400 µg folic acid daily (D+M+I)
Trial: 12356779
Drug: Isoflavone-rich soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-rich soy protein diet (approximately 90 mg of total isoflavones/day)
Trial: 10856150
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg twice daily (FP100BID)
Trial: 10856150
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 microg once daily (FP200QD)
Trial: 8857869
Drug: Structured depression
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured depression treatment program including behavioral treatment and counseling
Trial: 8857869
Drug: Structured depression
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured depression treatment program
Trial: 1535788
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate for 21 days combined with 250 micrograms levonorgestrel for the last ten days
Trial: 1535788
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol valerate for 21 days combined with 10 mg medroxyprogesterone acetate for the last ten days
Trial: 6318543
Drug: MK-521 20
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-521 20 mg once daily
Trial: 6318543
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MK-521 and Hydrochlorothiazide
Trial: 31264767
Drug: Sotagliflozin 75
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sotagliflozin 75 mg
Trial: 25926620
Drug: Telcagepant 140
RxNorm normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telcagepant 140 mg
Trial: 25282309
Drug: Regression analyses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regression analyses controlling for pre-treatment opioid dependence diagnosis, opioid misuse, and pain severity
Trial: 12234505
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine (20 cc of 2% intrarectal lidocaine 20 minutes before biopsy)
Trial: 7006882
Drug: Oral ETN
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ETN
Trial: 9847643
Drug: High-dose propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose propofol (0.3 mg/kg plus 10 mg/kg/h perfusion)
Trial: 9847643
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with nitroprusside (8 mg/kg/h perfusion)
Trial: 9734496
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 3000 mg/day
Trial: 1884720
Drug: Diltiazem 120-360
RxNorm normalized name: diltiazem hydrochloride 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 120-360 mg/day
Trial: 1884720
Drug: Metoprolol 50-200
RxNorm normalized name: metoprolol tartrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50-200 mg/day
Trial: 27040154
Drug: Carnosine 2
RxNorm normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine 2 g daily for 12 weeks
Trial: 11931782
Drug: 165 microg/injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 microg/injection
Trial: 11931782
Drug: 330 microg/injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 microg/injection (less intense regimen)
Trial: 11931782
Drug: 330 microg/injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 microg/injection (more intense regimen)
Trial: 11931782
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with intravitreous fomivirsen
Trial: 9056060
Drug: Sucralfate (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2000 mg twice daily for 5 days)
Trial: 3527513
Drug: Brotizolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam (0.25 mg or 0.5 mg)
Trial: 25577914
Drug: Baimai ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baimai ointment, fomentation, functional exercises
Trial: 23316290
Drug: Bromocriptine-QR (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine-QR (1.6 to 4.8 mg/day)
Trial: 21189853
Drug: labetalol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (0.25 mg/kg)
Trial: 21189853
Drug: esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol (0.5 mg/kg)
Trial: 21189853
Drug: control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (10 ml 0.9% saline)
Trial: 18373383
Drug: Gepirone-ER (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone-ER (20 to 80 mg/day, most patients received 60 or 80 mg/day by week 3)
Trial: 15747682
Drug: Single preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative dose of prophylactic antibiotic with no postoperative antibiotics
Trial: 15747682
Drug: Preoperative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative dose of antibiotics with postoperative antibiotics for 7 days
Trial: 10498024
Drug: Barrier gels
RxNorm normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier gels
Trial: 6203313
Drug: Verucid (comparative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verucid (comparative drug)
Trial: 24988179
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid treatment (1.9 g EPA and 1.5 g DHA)
Trial: 23724240
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment plus immunotherapy
Trial: 23724240
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with steroids and/or tacrolimus (Control)
Trial: 17369783
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy for neck pain
Trial: 1663261
Drug: WC3 rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC3 rotavirus vaccine
Trial: 2172394
Drug: Previous rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous rotavirus infection, high levels of WC3 neutralizing antibody, maternal serotype 1 neutralizing antibody (titer >= 30)
Trial: 22587973
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment combined with comprehensive rehabilitation therapy
Trial: 22587973
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation therapy only
Trial: 21086596
Drug: Microwave resonance
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microwave resonance therapy with 'fluctuating' frequency and varied wave range
Trial: 15890591
Drug: Intrarectal amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal amifostine (1,500 mg)
Trial: 15890591
Drug: Subcutaneous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous amifostine (500 mg)
Trial: 10605192
Drug: Antiretroviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral agents
Trial: 8620521
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day for 2 weeks
Trial: 8620521
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 150,000 IU human natural IL-2 (hnIL-2) per day
Trial: 8620521
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 300,000 IU human natural IL-2 (hnIL-2) per day
Trial: 6755208
Drug: Continue treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue treatment for 3 years
Trial: 6755208
Drug: Stop treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop treatment after 18 months or 2 years
Trial: 6755208
Drug: Continue treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue treatment for 2 years
Trial: 29279062
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy tablets
Trial: 29279062
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy drops
Trial: 29279062
Drug: Both tablets
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tablets and drops
Trial: 27154364
Drug: Omega-3 fish
RxNorm normalized name: Omega-3 Fish Oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fish oil supplementation at a dose of 60mg/Kg/day
Trial: 18540923
Drug: Gabapentin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,500 mg or 5 pills at bedtime for 6 weeks)
Trial: 14750898
Drug: Granulocyte Colony-Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) after high-dose chemotherapy with stem cell support
Trial: 14750898
Drug: Granulocyte Colony-Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF) in the treatment of established chemotherapy-induced febrile neutropenia
Trial: 8595995
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (high dosage)
Trial: 1883256
Drug: Clomipramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (up to 300 mg/d)
Trial: 17128840
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base
Trial: 30621746
Drug: Full-dose TNF
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TNF inhibitors (adalimumab, etanercept, infliximab, golimumab)
Trial: 30621746
Drug: Reduced-dose TNF
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose TNF inhibitors (approximately half the standard dose)
Trial: 30621746
Drug: Full-dose TNF
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TNF inhibitors
Trial: 30621746
Drug: Reduced-dose TNF
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose TNF inhibitors
Trial: 30278544
Drug: Dezocine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 0.15 mg/kg before anesthesia induction
Trial: 21517925
Drug: Mitiglinide 5
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 5 mg (fasted)
Trial: 21517925
Drug: Mitiglinide 10
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 10 mg (fasted)
Trial: 21517925
Drug: Mitiglinide 20
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mitiglinide 20 mg (fasted)
Trial: 21517925
Drug: Mitiglinide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiglinide (all doses)
Trial: 21057743
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no medical or non-medicated preparations)
Trial: 17951496
Drug: 8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/d of Synergy (inulin-type fructans)
Trial: 15699296
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75‐225 mg/d)
Trial: 15699296
Drug: Paroxetine (20‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20‐50 mg/d)
Trial: 12050266
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg, n = 10)
Trial: 12050266
Drug: Metformin (1275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1275 mg, n = 8)
Trial: 12050266
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Flutamide + Metformin, n = 13)
Trial: 10471871
Drug: Amoxicillin/clavulanate (Augmentin)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (Augmentin) and ticarcillin/clavulanate (Timentin)
Trial: 2043514
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided percutaneous aspiration and lavage of the gallbladder followed by intra‐lumenal instillation of 500 mg ampicillin (PALA)
Trial: 2043514
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with 500 mg of ampicillin every 6 hours for 5 days (Control)
Trial: 27644162
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for a minimum of 1 month
Trial: 21820829
Drug: Dose-modulated ECG-gated
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-modulated ECG-gated CT angiography